Clinical use of blood ptau217: plasma or serum? The matrix matters
Our data show that, when assays are reliable in serum, relative biomarker values vary across blood fractions, which most often prevents the use of a single cutoff for the two matrices. In addition, very high agreement was found between collection tube types, suggesting that ptau217 is similarly quantified regardless of the clotting factor used. However, once again the data underscores caution when merging results from samples collected under different protocols.
Authors
- Henrik Zetterberg
- Nicholas James Ashton (ORCID: https://orcid.org/0000-0002-3579-8804)
- Hanna Huber (ORCID: https://orcid.org/0009-0004-3080-6870)
- Hlin Kvartsberg (ORCID: https://orcid.org/0000-0002-4481-508X)
- Burak Arslan (ORCID: https://orcid.org/0000-0001-7229-3226)
- S Janelidze
- Kaj Blennow
- Pedro Rosa‐Neto (ORCID: https://orcid.org/0000-0001-9116-1376)
- Oskar H. Hansson
- Kübra Tan (ORCID: https://orcid.org/0000-0002-9092-2118)
- Andrea Benedet
- Ilaria Pola
- Guglielmo Di Molfetta
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Lund University (SE)
- German Center for Neurodegenerative Diseases (DE)
- McGill University Health Centre (CA)
- Sorbonne Université (FR)
- Profu (Sweden) (SE)
- Institut de Psychiatrie et Neurosciences de Paris (FR)
- Skåne University Hospital (SE)
- Banner Alzheimer’s Institute
- University College London (GB)
- McGill University (CA)
- University of Gothenburg (SE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108733
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00